JP2626889B2 - ブリオスタチン類 - Google Patents

ブリオスタチン類

Info

Publication number
JP2626889B2
JP2626889B2 JP62183803A JP18380387A JP2626889B2 JP 2626889 B2 JP2626889 B2 JP 2626889B2 JP 62183803 A JP62183803 A JP 62183803A JP 18380387 A JP18380387 A JP 18380387A JP 2626889 B2 JP2626889 B2 JP 2626889B2
Authority
JP
Japan
Prior art keywords
acid
bryostatin
active ingredient
methanol
bryostatins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP62183803A
Other languages
English (en)
Japanese (ja)
Other versions
JPS63183585A (ja
Inventor
アール ペチット ジョージ
エル ヘラルド チェリー
カマノ ヨシアキ
イー リート ジョン
Original Assignee
アリゾナ ボ−ド オブ リ−ゼンツ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリゾナ ボ−ド オブ リ−ゼンツ filed Critical アリゾナ ボ−ド オブ リ−ゼンツ
Publication of JPS63183585A publication Critical patent/JPS63183585A/ja
Application granted granted Critical
Publication of JP2626889B2 publication Critical patent/JP2626889B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Vending Machines For Individual Products (AREA)
JP62183803A 1986-07-28 1987-07-24 ブリオスタチン類 Expired - Fee Related JP2626889B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/889,946 US4833257A (en) 1986-07-28 1986-07-28 Compositions of matter and methods of using same
US889946 1986-07-28

Publications (2)

Publication Number Publication Date
JPS63183585A JPS63183585A (ja) 1988-07-28
JP2626889B2 true JP2626889B2 (ja) 1997-07-02

Family

ID=25396026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62183803A Expired - Fee Related JP2626889B2 (ja) 1986-07-28 1987-07-24 ブリオスタチン類

Country Status (8)

Country Link
US (1) US4833257A (OSRAM)
EP (1) EP0264173B1 (OSRAM)
JP (1) JP2626889B2 (OSRAM)
AT (1) ATE71627T1 (OSRAM)
CA (1) CA1305476C (OSRAM)
DE (1) DE3776063D1 (OSRAM)
ES (1) ES2038664T3 (OSRAM)
GR (1) GR3004061T3 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256646A (en) * 1990-07-27 1993-10-26 Bristol-Myers Squibb Company Antiviral antibiotic BU-4224V
US5072004A (en) * 1990-12-31 1991-12-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthetic conversion of bryostatin 2 into bryostatin 1
US5196447A (en) * 1991-08-08 1993-03-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting On Behalf Of Arizona State University Neristatin 1
US5436400A (en) * 1993-01-19 1995-07-25 Arizona Board Of Regents Isolation and structure of spongistatin 1
US5393897A (en) * 1993-07-02 1995-02-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structure of spongistatins 5,7,8 and 9
US5478861A (en) * 1994-02-18 1995-12-26 Harbor Branch Oceanographic Institution, Inc. Cytotoxic macrolides and methods of use
US5684036A (en) * 1994-02-18 1997-11-04 Harbor Branch Oceanographic Institution, Inc. Cytotoxic macrolides and methods of use
AU2337997A (en) * 1996-03-20 1997-10-10 Arizona Board Of Regents, The Method of treating cancer using c-26 modified bryostatin
JP2003515601A (ja) 1999-11-30 2003-05-07 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ ブリオスタチンアナログ、合成方法および使用
US7256286B2 (en) * 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
CA2416788A1 (en) * 2000-07-31 2002-02-07 Tamar Tennenbaum Methods and pharmaceutical compositions comprising protein kinase c isoforms for healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7842727B2 (en) * 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US20040235889A1 (en) * 2001-05-02 2004-11-25 Miao-Kun Sun Carbonic anhydrase activator for enhancing learning and memory
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
WO2004004641A2 (en) * 2002-07-02 2004-01-15 Blanchette Rockefeller Neurosciences Institute PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPα SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
WO2003093275A1 (en) * 2002-04-30 2003-11-13 University Of North Carolina At Chapel Hill A bryostatin composition
EP1511477A4 (en) * 2002-05-22 2008-04-09 Errant Gene Therapeutics Llc HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETO-EPOXYDE COMPOUNDS
AU2003291097A1 (en) * 2002-11-20 2004-06-15 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
AU2004263009B2 (en) * 2003-08-07 2009-12-24 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
EP1817020A4 (en) * 2004-11-08 2012-11-21 Errant Gene Therapeutics Inc INHIBITORS OF HISTONATE ACETYLASE
WO2007016202A1 (en) * 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
WO2007026356A2 (en) * 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
EP2073801A1 (en) 2006-07-28 2009-07-01 Blanchette Rockefeller Neurosciences Institute Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
EP2737904A3 (en) 2007-02-09 2014-12-17 Blanchette Rockefeller Neurosciences, Institute Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury
EP2754448A3 (en) * 2007-02-09 2014-12-24 Blanchette Rockefeller Neurosciences, Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
CN102755649A (zh) * 2007-07-30 2012-10-31 希尔洛有限公司 药物组合物及相关方法
WO2010097788A2 (en) * 2009-02-24 2010-09-02 Healor Ltd. Visfatin therapeutic agents for the treatment of acne and other conditions
EP2599494A1 (en) 2010-01-11 2013-06-05 Healor Ltd. PKC inhibitors for the treatment of inflammatory disease or disorder
WO2012006516A2 (en) 2010-07-08 2012-01-12 Alkon Daniel L Dag-type and indirect protein kinase c activators and anticoagulant for the treatment of stroke
EP2605773A1 (en) 2010-08-19 2013-06-26 Blanchette Rockefeller Neurosciences, Institute Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
EP2776018B1 (en) 2011-11-13 2021-08-25 Cognitive Research Enterprises, Inc. Pkc activators and combinations thereof
US20150291616A1 (en) * 2012-11-27 2015-10-15 Aphios Corporation Bryoid compositions, methods of making and use thereof
US20180030095A1 (en) 2015-02-13 2018-02-01 George Robert Pettit Silstatin compounds
CA2985625A1 (en) 2015-05-11 2016-11-17 Alkon, Daniel L. Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
US11629167B2 (en) 2017-11-09 2023-04-18 Arizona Board Of Regents On Behalf Of Arizona State University Betulastatin compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
JPS60174418A (ja) * 1984-02-18 1985-09-07 Ishikawajima Harima Heavy Ind Co Ltd 下水あるいはし尿汚泥等の流動層式焼却装置
US4611066A (en) * 1984-08-10 1986-09-09 Arizona State University Bryostatins 4 to 8

Also Published As

Publication number Publication date
DE3776063D1 (en) 1992-02-27
US4833257A (en) 1989-05-23
ES2038664T3 (es) 1993-08-01
GR3004061T3 (OSRAM) 1993-03-31
EP0264173A3 (en) 1988-07-13
EP0264173A2 (en) 1988-04-20
ATE71627T1 (de) 1992-02-15
CA1305476C (en) 1992-07-21
EP0264173B1 (en) 1992-01-15
JPS63183585A (ja) 1988-07-28

Similar Documents

Publication Publication Date Title
JP2626889B2 (ja) ブリオスタチン類
US4560774A (en) Macrocyclic lactones
US4611066A (en) Bryostatins 4 to 8
Kupchan et al. Tumor inhibitors. 122. The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides
Ishibashi et al. Scytophycins, cytotoxic and antimycotic agents from the cyanophyte Scytonema pseudohofmanni
US4289851A (en) Process for producing cyclosporin derivatives
JPH02311496A (ja) ドラスタチン１５とその応用
CA1148936A (en) Triterpenic saponin having pharmacological potency
CA1297108C (en) Substance, composition of matter and method of using same
CA1060003A (en) N-trifluoroacetyladriamycin-14-alkanoates and therapeutic compositions containing same
WO2007038868A2 (en) Novel enediyne compound and uses thereof
SHU et al. Metabolism of paeoniflorin and related compounds by human intestinal bacteria. II. Structures of 7S-and 7R-paeonimetabolines I and II formed by Bacteroides fragilis and Lactobacillus brevis
Kalinovskaya et al. New angucyclines and antimicrobial diketopiperazines from the marine mollusk-derived actinomycete Saccharothrix espanaensis An 113
US4388457A (en) Phyllanthostatin compounds
JP3639973B2 (ja) スポンギスタチン６
Ma et al. Study of antimalarial activity of chemical constituents from Diospyros quaesita
EP0014425B1 (en) Anthracycline glycosides, methods for the production thereof and therapeutical compositions containing same
US4895852A (en) Antitumor alkaloids
US4868204A (en) Mycalamide compounds, compositions thereof and methods of preparation and use
WO1996032388A1 (en) Antheliatin, zahavin a and zahavin b: new cytotoxic xenicane diterpenes
US5514708A (en) Cytotoxic metabolites from Myriapora truncata
WO2001010869A1 (en) Bioactive compound
CN121405669A (zh) 生物碱类化合物及其制备方法和在抗肿瘤中的应用
CN114262354A (zh) 一种化合物及其用途
JPH01290627A (ja) 抗腫瘍剤

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees